All In Biotech

NDA 017441 · Allergan

Infed

Iron Dextran · Injection

Priority review

Last checked: Nov 19, 2026Latest source record: Aug 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

Apr 29, 1974

Approved uses

1

Original approval plus efficacy supplements

Registered trials

147

40 Phase 3, 12 recruiting

FAERS reports

1,486

956 serious, 124 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

BOXED WARNING WARNING: RISK FOR ANAPHYLACTIC-TYPE REACTIONS Anaphylactic-type reactions, including fatalities, have been reported following the parenteral administration of iron dextran injection. Have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during INFeD administration. Administer a test INFeD dose prior to the first therapeutic dose. If no signs or symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic INFeD dose. During all INFeD administrations, observe for signs or symptoms of anaphylactic-type reactions. Fatal reactions have been reported following the test dose of iron dextran injection. Fatal reactions have also occurred in situations where the test dose was tolerated. Use INFeD only in patients in whom clinical and laboratory investigations have...

What it is approved for

From the label in effect Apr 15, 2026.

INFeD is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron. INFeD, an iron replacement product, is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or an unsatisfactory response to oral iron. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 29, 1974 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
1 products under this application
  • INFED · IRON DEXTRAN EQ 100MG IRON/2ML (EQ 50MG IRON/ML) · INJECTABLE, INJECTION · Prescription · TE BP

Clinical trials

Interventional ClinicalTrials.gov studies with "Iron Dextran" as an intervention, any sponsor and status, largest first.

All 147 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea264
  • infusion related reaction167
  • nausea126
  • flushing115
  • anaphylactic reaction112
  • back pain111
  • chest pain102
  • dizziness88
  • chest discomfort85
  • pruritus81
  • off label use80
  • hypotension72

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200445
200549
200648
200746
200843
200939
201036
201139
201260
201326
201417
201534
201645
201747
201868
201960
202061
202199
202291
202392
2024143
2025172
2026126

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Infed (Iron Dextran Complex) · HCPCS J1750

2024 spending

$11.1M

Beneficiaries

25,311

41,411 claims

Per beneficiary

$440

2024 ASP limit $17.57 per unit

View as table
YearSpending
2020$5,014,208
2021$7,317,114
2022$7,509,332
2023$5,195,404
2024$11,137,455

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 112 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.